NCT06962462Not yet recruiting
Daily Tadalafil in Diabetic ED Patients
Effect of Daily Tadalafil Therapy on Endothelin-1 and E-Selectin in Diabetic Patients With Erectile Dysfunction
Source: ClinicalTrials.gov · Last updated 8 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 30 Apr 2025
- Start date
- 5 May 2025
- Primary completion date
- 5 Aug 2025
- Lead sponsor
- South Valley University
- Diseases
- Type 2 diabetes
- NCT number
- NCT06962462
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 5 May 2025 to the primary completion date, 5 Aug 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of pelvic trauma or major pelvic surgery Pacientes con hipogonadismo o hiperprolactinemia Chronic liver disease or cardiovascular disorders Chronic use of central nervous system drugs, anti-androgenic drugs, or Tramadol Smokers Non-vasculogenic erectile dysfunction Known allergy to tadalafil
Who the study is looking for
- Male patients aged between 30 and 60 yearsز Diagnosed with diabetes mellitus Suffering from erectile dysfunction No history of hypertension or other systemic diseases
Age in the registry: 30 years to 60 years · Sex: Male · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.